Determining Risk Factors That Affect Progression in Patients with Nonproliferative Diabetic Retinopathy

Dalbert J Chen; Jacky C Kuo; Alex J Wright; Alice Z Chuang; Wenyaw Chan; Robert M Feldman; Eric L Crowell

doi:10.1155/2021/6064525

Determining Risk Factors That Affect Progression in Patients with Nonproliferative Diabetic Retinopathy

J Ophthalmol. 2021 Nov 30:2021:6064525. doi: 10.1155/2021/6064525. eCollection 2021.

Authors

Dalbert J Chen¹, Jacky C Kuo², Alex J Wright^{1

3

4}, Alice Z Chuang¹, Wenyaw Chan², Robert M Feldman^{1

3

4}, Eric L Crowell^{1

3

4}

Affiliations

¹ Ruiz Department of Ophthalmology and Visual Science, McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), 6431 Fannin St., MSB 7.204, Houston, TX 77030, USA.
² Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston (UTHealth), 1200 Pressler St., RAS E827, Houston, TX 77030, USA.
³ Robert Cizik Eye Clinic, 6400 Fannin St., Suite 1800, Houston, TX 77030, USA.
⁴ Lyndon B. Johnson Hospital, Harris Health, 5656 Kelley St., Houston, TX 77026, USA.

Abstract

Purpose: To determine risk factors that affect nonproliferative diabetic retinopathy (NPDR) progression and establish a predictive model to estimate the probability of and time to progression in NPDR. Patients and Methods. Charts of diabetic patients who received an initial eye exam between 2010 and 2017 at our county hospital were included. Patients with proliferative diabetic retinopathy (PDR), fewer than 2 years of follow-up, or fewer than 3 clinic visits were excluded. Demographics and baseline systemic and ocular characteristics were recorded. Follow-up mean annual HbA1c and blood pressure, best-corrected visual acuity, and the number of antivascular endothelial growth factor treatments were recorded. Stage and date of progression were recorded. A 5-state nonhomogeneous continuous-time Markov chain with a backward elimination model was used to identify risk factors and estimate their effects on progression.

Results: Two hundred thirty patients were included. Initially, 65 eyes (28.3%) had no retinopathy; 73 (31.7%) mild NPDR; 60 (26.1%) moderate NPDR; and 32 (13.9%) severe NPDR. Patients were followed for a mean of 5.8 years (±2.0 years; range 2.1-9.4 years). 164 (71.3%) eyes progressed during the follow-up. Time-independent risk factors affecting progression rate were age (hazard ratio (HR) = 0.99, P=0.047), duration of diabetes (HR = 1.02, P=0.018), and Hispanic ethnicity (HR = 1.31, P=0.068). Mean sojourn times at mean age, duration of diabetes, and annual HbA1c for a non-Hispanic patient were estimated to be 3.03 (±0.97), 4.63 (±1.21), 6.18 (±1.45), and 4.85 (±1.25) years for no retinopathy, mild NPDR, moderate NPDR, and severe NPDR, respectively. Each 1% increase in HbA1c annually diminished sojourn times by 15%, 10%, 7%, and 10% for no retinopathy, mild NPDR, moderate NPDR, and severe NPDR, respectively.

Conclusion: HbA1c level is a significant modifiable risk factor in controlling the progression of DR. The proposed model could be used to predict the time and rate of progression based on an individual's risk factors. A prospective multicenter study should be conducted to further validate our model.